IL214443A0 - Enhanced migraine treatments based on ghrelin mimetics - Google Patents
Enhanced migraine treatments based on ghrelin mimeticsInfo
- Publication number
- IL214443A0 IL214443A0 IL214443A IL21444311A IL214443A0 IL 214443 A0 IL214443 A0 IL 214443A0 IL 214443 A IL214443 A IL 214443A IL 21444311 A IL21444311 A IL 21444311A IL 214443 A0 IL214443 A0 IL 214443A0
- Authority
- IL
- Israel
- Prior art keywords
- enhanced
- treatments based
- migraine treatments
- ghrelin mimetics
- ghrelin
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2121/00—Preparations for use in therapy
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Otolaryngology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US15612909P | 2009-02-27 | 2009-02-27 | |
| PCT/US2010/025725 WO2010099522A1 (en) | 2009-02-27 | 2010-03-01 | Enhanced migraine treatments based on ghrelin mimetics |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL214443A0 true IL214443A0 (en) | 2011-09-27 |
Family
ID=42144981
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL214443A IL214443A0 (en) | 2009-02-27 | 2011-08-03 | Enhanced migraine treatments based on ghrelin mimetics |
Country Status (17)
| Country | Link |
|---|---|
| US (2) | US8486976B2 (zh) |
| EP (1) | EP2400986B1 (zh) |
| JP (1) | JP6041491B2 (zh) |
| KR (2) | KR20160136473A (zh) |
| CN (1) | CN102333545B (zh) |
| AU (1) | AU2010217792B2 (zh) |
| BR (1) | BRPI1008698A2 (zh) |
| CA (1) | CA2752813C (zh) |
| EA (1) | EA021055B1 (zh) |
| ES (1) | ES2558701T3 (zh) |
| IL (1) | IL214443A0 (zh) |
| MX (1) | MX2011008413A (zh) |
| NO (1) | NO20111303A1 (zh) |
| SG (1) | SG174158A1 (zh) |
| TW (1) | TWI457331B (zh) |
| UA (1) | UA105657C2 (zh) |
| WO (1) | WO2010099522A1 (zh) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20130281701A1 (en) * | 2004-06-29 | 2013-10-24 | Helsinn Therapeutics (U.S.), Inc. | Crystal forms of anamorelin |
| EP2440180B1 (en) * | 2009-06-12 | 2014-08-27 | Helsinn Healthcare S.A. | Ipamorelin diacetate injection and infusion solutions |
| CA2859173A1 (en) * | 2011-12-19 | 2013-06-27 | Map Pharmaceuticals, Inc. | Novel iso-ergoline derivatives |
| US10039813B2 (en) | 2012-02-07 | 2018-08-07 | Massachusetts Institute Of Technology | Use of antagonists of ghrelin or ghrelin receptor to prevent or treat stress-sensitive psychiatric illness |
| JO3353B1 (ar) | 2012-04-20 | 2019-03-13 | Ono Pharmaceutical Co | شكل صلب معزول من أحادي هيدروكلوريد أناموريلين بنسبة مولارية منخفضة من الكلوريد: أناموريلين ومحتوى منخفض من مذيب عضوي متبقي |
| US9724396B2 (en) | 2013-03-15 | 2017-08-08 | Massachusetts Institute Of Technology | Use of antagonists of growth hormone or growth hormone receptor to prevent or treat stress-sensitive psychiatric illness |
| WO2016138099A1 (en) | 2015-02-24 | 2016-09-01 | Massachusetts Institute Of Technology | Use of ghrelin or functional ghrelin receptor agonists to prevent and treat stress-sensitive psychiatric illness |
| GB2571696B (en) | 2017-10-09 | 2020-05-27 | Compass Pathways Ltd | Large scale method for the preparation of Psilocybin and formulations of Psilocybin so produced |
| CA3138094A1 (en) | 2019-04-17 | 2020-10-22 | Compass Pathfinder Limited | Methods for treating anxiety disorders, headache disorders, and eating disorders with psilocybin |
| KR20220027884A (ko) * | 2019-05-31 | 2022-03-08 | 레터럴 아이피 피티와이 리미티드 | 펩티드 및 그의 용도 |
| BR112022002767A2 (pt) | 2019-08-30 | 2022-05-10 | Helsinn Healthcare Sa | Métodos de fabricação de um comprimido de cloridrato de anamorelina, comprimidos e método para melhorar um ou mais sintomas de caquexia de câncer |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SK281963B6 (sk) * | 1993-12-23 | 2001-09-11 | Novo Nordisk A/S | Zlúčeniny ovplyvňujúce uvoľňovanie rastového hormónu, farmaceutické prostriedky s ich obsahom a ich použitie |
| WO1997023508A1 (en) * | 1995-12-22 | 1997-07-03 | Novo Nordisk A/S | Compounds with growth hormone releasing properties |
| DE69734215T2 (de) * | 1996-07-22 | 2006-06-29 | Novo Nordisk A/S | Verbindungen mit Wachstumshormon-freisetzenden Eigenschaften |
| US5872145A (en) * | 1996-08-16 | 1999-02-16 | Pozen, Inc. | Formulation of 5-HT agonist and NSAID for treatment of migraine |
| US6083908A (en) * | 1998-01-16 | 2000-07-04 | Novo Nordisk A/S | Compounds with growth hormone releasing properties |
| US6303620B1 (en) * | 1998-05-11 | 2001-10-16 | Novo Nordisk A/S | Compounds with growth hormone releasing properties |
| US6919315B1 (en) * | 1998-06-30 | 2005-07-19 | Novo Nordisk A/S | Compounds with growth hormone releasing properties |
| ES2234324T3 (es) * | 1998-11-02 | 2005-06-16 | MERCK & CO., INC. | Combinaciones de un agonista 5ht1b/1d y un inhibidor selectivo de cox-2 para el tratamiento de la migraña. |
| US6566337B1 (en) * | 1998-11-03 | 2003-05-20 | Novo Nordisk A/S | Compounds with growth hormone releasing properties |
| UA73530C2 (uk) * | 1999-11-10 | 2005-08-15 | Ново Нордіск А/С | Сполука з властивостями вивільнювати гормон росту |
| CA2395996A1 (en) * | 1999-12-28 | 2001-07-05 | Kaken Pharmaceutical Co., Ltd. | Neuroprotective drug |
| EP1312363A1 (en) * | 2001-09-28 | 2003-05-21 | Pfizer Products Inc. | Methods of treatment and kits comprising a growth hormone secretagogue |
| KR20070010151A (ko) * | 2004-03-30 | 2007-01-22 | 사파이어 세라퓨틱스, 인크. | 성장 호르몬 분비촉진제를 이용하여 ｃ-반응성 단백질을감소시키는 방법 |
| ES2388501T3 (es) * | 2004-08-12 | 2012-10-16 | Helsinn Healthcare S.A. | Uso de secretagogos de la hormona de crecimiento para estimular la motilidad del sistema gastrointestinal |
| JP2009535336A (ja) | 2006-04-25 | 2009-10-01 | コーワ ファーマシューティカルズ アメリカ，インコーポレイティド | 片頭痛治療用の固定組合せ剤形 |
| TWI429436B (zh) * | 2007-04-10 | 2014-03-11 | Helsinn Therapeutics Us Inc | 使用生長激素促泌素治療或預防嘔吐之方法 |
-
2010
- 2010-01-03 UA UAA201111390A patent/UA105657C2/uk unknown
- 2010-02-26 TW TW099105584A patent/TWI457331B/zh active
- 2010-02-26 US US12/713,531 patent/US8486976B2/en active Active
- 2010-03-01 EP EP10707741.4A patent/EP2400986B1/en not_active Not-in-force
- 2010-03-01 BR BRPI1008698A patent/BRPI1008698A2/pt not_active IP Right Cessation
- 2010-03-01 CN CN201080009795.2A patent/CN102333545B/zh not_active Expired - Fee Related
- 2010-03-01 EA EA201171091A patent/EA021055B1/ru not_active IP Right Cessation
- 2010-03-01 SG SG2011061496A patent/SG174158A1/en unknown
- 2010-03-01 MX MX2011008413A patent/MX2011008413A/es active IP Right Grant
- 2010-03-01 AU AU2010217792A patent/AU2010217792B2/en not_active Ceased
- 2010-03-01 KR KR1020167032461A patent/KR20160136473A/ko not_active Application Discontinuation
- 2010-03-01 ES ES10707741.4T patent/ES2558701T3/es active Active
- 2010-03-01 CA CA2752813A patent/CA2752813C/en not_active Expired - Fee Related
- 2010-03-01 KR KR1020117022565A patent/KR101707666B1/ko active IP Right Grant
- 2010-03-01 JP JP2011552215A patent/JP6041491B2/ja active Active
- 2010-03-01 WO PCT/US2010/025725 patent/WO2010099522A1/en active Application Filing
-
2011
- 2011-08-03 IL IL214443A patent/IL214443A0/en unknown
- 2011-09-26 NO NO20111303A patent/NO20111303A1/no not_active Application Discontinuation
-
2013
- 2013-06-18 US US13/920,863 patent/US8673947B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| JP2012519184A (ja) | 2012-08-23 |
| KR20160136473A (ko) | 2016-11-29 |
| JP6041491B2 (ja) | 2016-12-07 |
| AU2010217792A1 (en) | 2011-08-25 |
| CN102333545B (zh) | 2014-03-19 |
| EA021055B1 (ru) | 2015-03-31 |
| EP2400986A1 (en) | 2012-01-04 |
| CN102333545A (zh) | 2012-01-25 |
| BRPI1008698A2 (pt) | 2016-03-08 |
| TW201035071A (en) | 2010-10-01 |
| KR20110126155A (ko) | 2011-11-22 |
| CA2752813C (en) | 2017-03-28 |
| NO20111303A1 (no) | 2011-09-26 |
| WO2010099522A1 (en) | 2010-09-02 |
| US20130289068A1 (en) | 2013-10-31 |
| EA201171091A1 (ru) | 2012-04-30 |
| KR101707666B1 (ko) | 2017-02-16 |
| US8673947B2 (en) | 2014-03-18 |
| SG174158A1 (en) | 2011-10-28 |
| ES2558701T3 (es) | 2016-02-08 |
| CA2752813A1 (en) | 2010-09-02 |
| AU2010217792B2 (en) | 2015-10-22 |
| US20100222388A1 (en) | 2010-09-02 |
| EP2400986B1 (en) | 2015-10-14 |
| MX2011008413A (es) | 2011-09-22 |
| US8486976B2 (en) | 2013-07-16 |
| UA105657C2 (uk) | 2014-06-10 |
| TWI457331B (zh) | 2014-10-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL214443A0 (en) | Enhanced migraine treatments based on ghrelin mimetics | |
| GB2466465B (en) | Authentication | |
| IL206654A0 (en) | Combination therapy | |
| HUE056278T2 (hu) | Elhízás kezelése | |
| EP2350945A4 (en) | UNIFIED IDENTITY VERIFICATION | |
| EP2430548A4 (en) | AUTHENTICATION OF STORAGE DEVICE | |
| EP2430792A4 (en) | HTTP AUTHENTICATION | |
| GB201022002D0 (en) | Authentication apparatus | |
| EP2382734A4 (en) | VERIFICATION OF SOFTWARE APPLICATION | |
| EP2405869A4 (en) | TREATMENT OF GRAVITY | |
| EP2406748A4 (en) | EFFICIENT TWO-FACTOR AUTHENTICATION | |
| GB0808752D0 (en) | Identity verification | |
| EP2430562A4 (en) | INTERACTIVE AUTHENTICATION CHAIN | |
| EP2420115A4 (en) | BACK BORE VERIFICATION FEATURE | |
| GB0811992D0 (en) | Treatment | |
| GB0917325D0 (en) | Flavour enhancement | |
| GB0805848D0 (en) | Device interconnects | |
| IL208001A0 (en) | Improved anticancer treatments | |
| EP2337385A4 (en) | AUTHENTICATION SERVER | |
| GB0916997D0 (en) | Combination therapy | |
| GB0822077D0 (en) | Novel treatments | |
| TWI365969B (en) | Aiming device | |
| EP2267630A4 (en) | AUTHENTICATION SERVER AND LINE SERVER | |
| GB0803948D0 (en) | Combination therapy | |
| GB0805912D0 (en) | Treatment |